Biotech Values

[oc631]

Indeed it is, and ABBV is arguably the leader. This is in sharp contrast to the sentiment on my Twitter feed, where people seems to think the race is over and GILD has won.

-Have you had further discussion about the weakness with the Sofo/Riba combo in GT3?

-The glaring differences in SVR rates between GT2 and GT3?

-How the FDA will view the pooled data?

-Has anyone speculated [besides me] what kind of SVR rates we would see using Sofo/PegRiba in GT3 as opposed to the sub-optimal results seen using Sofo/Riba?


No one wants to rock the boat or look at things impartially.